{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T07:57:30Z","timestamp":1783238250104,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008318","name":"Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016391","name":"Societat Catalana de Digestologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-ES-987-5349"],"award-info":[{"award-number":["IN-ES-987-5349"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jhepr.2022.100580","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:24:18Z","timestamp":1663039458000},"page":"100580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-411X","authenticated-orcid":false,"given":"Sabela","family":"Lens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-0380","authenticated-orcid":false,"given":"Anna","family":"Miralpeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mont","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Martr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-7557","authenticated-orcid":false,"given":"Sergio","family":"Rodr\u00edguez-Tajes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Saludes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Reyes-Urue\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Maj\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Colom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-1764","authenticated-orcid":false,"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100580_bib1","first-page":"1","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 \u2013 what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.jhepr.2022.100580_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","article-title":"Stigma, discrimination and the health of illicit drug users","volume":"88","author":"Ahern","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhepr.2022.100580_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","article-title":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","volume":"68","author":"Fraser","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100580_bib4","series-title":"Report of the WHO global partners\u2019 meeting on hepatitis elimination","year":"2020"},{"key":"10.1016\/j.jhepr.2022.100580_bib5","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100580_bib6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jvh.12859","article-title":"Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era","volume":"25","author":"Falade-Nwulia","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100580_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080216","article-title":"High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study","volume":"8","author":"Sacks-Davis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100580_bib8","author":"de Catalunya"},{"key":"10.1016\/j.jhepr.2022.100580_bib9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/09540121.2016.1164290","article-title":"Implementation of rapid HIV and HCV testing within harm reduction programmes for people who inject drugs: a pilot study","volume":"28","author":"Fernandez-Lopez","year":"2016","journal-title":"AIDS Care"},{"key":"10.1016\/j.jhepr.2022.100580_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102734","article-title":"Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain","volume":"80","author":"Saludes","year":"2020","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhepr.2022.100580_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.103057","article-title":"The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: major gaps for migrants","volume":"90","author":"Folch","year":"2021","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhepr.2022.100580_bib12","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.jhepr.2022.100580_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jvh.12809","article-title":"Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain","volume":"25","author":"Saludes","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100580_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.drugpo.2019.10.012","article-title":"Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia","volume":"74","author":"Saludes","year":"2019","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhepr.2022.100580_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-40099-3","article-title":"Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay","volume":"9","author":"Saludes","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2022.100580_bib16","first-page":"1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"1253","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100580_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103135","article-title":"High HCV cure rates among people who inject drugs and have suboptimal adherence: a patient-centered approach to HCV models of care","volume":"93","author":"Norton","year":"2021","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhepr.2022.100580_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100580_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s12879-020-05426-4","article-title":"Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment","volume":"20","author":"Torrens","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100580_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-015-1479-x","article-title":"Impact of unstable housing on all-cause mortality among persons who inject drugs. Health behavior, health promotion and society","volume":"15","author":"Zivanovic","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2022.100580_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.drugalcdep.2013.03.009","article-title":"The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD","volume":"132","author":"Linton","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhepr.2022.100580_bib22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"Rossi","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100580_bib23","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/cid\/ciz693","article-title":"Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy","volume":"70","author":"Akiyama","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100580_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100580_bib25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cix126","article-title":"Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV","volume":"64","author":"Young","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100580_bib26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2022.100580_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","article-title":"Self-report among injecting drug users: a review","volume":"51","author":"Darke","year":"1998","journal-title":"Drug Alcohol Depend"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:29:00Z","timestamp":1762900140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2589555922001525"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100580","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100580"}}